Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Comparing the effects of atrazine and an environmentally relevant mixture on estrogen-responsive gene expression in the northern leopard frog and the fathead minnow.

Ali JM, Knight LA, D'Souza DL, Kolok AS.

Environ Toxicol Chem. 2018 Apr;37(4):1182-1188. doi: 10.1002/etc.4069. Epub 2018 Feb 15.

PMID:
29314190
2.

Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy.

Jain S, Lyons CA, Walker SM, McQuaid S, Hynes SO, Mitchell DM, Pang B, Logan GE, McCavigan AM, O'Rourke D, McArt DG, McDade SS, Mills IG, Prise KM, Knight LA, Steele CJ, Medlow PW, Berge V, Katz B, Loblaw DA, Harkin DP, James JA, O'Sullivan JM, Kennedy RD, Waugh DJ.

Ann Oncol. 2018 Jan 1;29(1):215-222. doi: 10.1093/annonc/mdx637.

3.

Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology.

Walker SM, Knight LA, McCavigan AM, Logan GE, Berge V, Sherif A, Pandha H, Warren AY, Davidson C, Uprichard A, Blayney JK, Price B, Jellema GL, Steele CJ, Svindland A, McDade SS, Eden CG, Foster C, Mills IG, Neal DE, Mason MD, Kay EW, Waugh DJ, Harkin DP, Watson RW, Clarke NW, Kennedy RD.

Eur Urol. 2017 Oct;72(4):509-518. doi: 10.1016/j.eururo.2017.03.027. Epub 2017 Apr 10.

4.

Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer.

Parkes EE, Walker SM, Taggart LE, McCabe N, Knight LA, Wilkinson R, McCloskey KD, Buckley NE, Savage KI, Salto-Tellez M, McQuaid S, Harte MT, Mullan PB, Harkin DP, Kennedy RD.

J Natl Cancer Inst. 2016 Oct 5;109(1). pii: djw199. Print 2017 Jan.

5.

De novo Assembly and Analysis of the Northern Leopard Frog Rana pipiens Transcriptome.

Christenson MK, Trease AJ, Potluri LP, Jezewski AJ, Davis VM, Knight LA, Kolok AS, Davis PH.

J Genomics. 2014 Oct 1;2:141-9. doi: 10.7150/jgen.9760. eCollection 2014.

6.

The spring runoff in Nebraska's (USA) Elkhorn River watershed and its impact on two sentinel organisms.

Knight LA, Christenson MK, Trease AJ, Davis PH, Kolok AS.

Environ Toxicol Chem. 2013 Jul;32(7):1544-51. doi: 10.1002/etc.2220. Epub 2013 May 28.

7.

Development and preliminary evaluation of an integrated treatment targeting parenting and depressive symptoms in mothers of children with attention-deficit/hyperactivity disorder.

Chronis-Tuscano A, Clarke TL, O'Brien KA, Raggi VL, Diaz Y, Mintz AD, Rooney ME, Knight LA, Seymour KE, Thomas SR, Seeley J, Kosty D, Lewinsohn P.

J Consult Clin Psychol. 2013 Oct;81(5):918-25. doi: 10.1037/a0032112. Epub 2013 Mar 11.

8.

The effect of tricyclic antidepressants on cutaneous melanoma cell lines and primary cell cultures.

Parker KA, Glaysher S, Hurren J, Knight LA, McCormick D, Suovouri A, Amberger-Murphy V, Pilkington GJ, Cree IA.

Anticancer Drugs. 2012 Jan;23(1):65-9. doi: 10.1097/CAD.0b013e32834b1894.

PMID:
21897201
9.

The anti-estrogenic activity of sediments from agriculturally intense watersheds: assessment using in vivo and in vitro assays.

Sellin Jeffries MK, Conoan NH, Cox MB, Sangster JL, Balsiger HA, Bridges AA, Cowman T, Knight LA, Bartelt-Hunt SL, Kolok AS.

Aquat Toxicol. 2011 Sep;105(1-2):189-98. doi: 10.1016/j.aquatox.2011.04.008. Epub 2011 Apr 22.

10.

Quality assurance and good laboratory practice.

Knight LA, Cree IA.

Methods Mol Biol. 2011;731:115-24. doi: 10.1007/978-1-61779-080-5_10.

PMID:
21516402
11.

The molecular basis of the chemosensitivity of metastatic cutaneous melanoma to chemotherapy.

Parker KA, Glaysher S, Polak M, Gabriel FG, Johnson P, Knight LA, Poole M, Narayanan A, Hurren J, Cree IA.

J Clin Pathol. 2010 Nov;63(11):1012-20. doi: 10.1136/jcp.2010.080119. Epub 2010 Oct 5.

PMID:
20924094
12.

Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy.

Glaysher S, Gabriel FG, Johnson P, Polak M, Knight LA, Parker K, Poole M, Narayanan A, Cree IA; NHS Collaborative Research Programme for Predictive Oncology.

Br J Cancer. 2010 Aug 24;103(5):656-62. doi: 10.1038/sj.bjc.6605817. Epub 2010 Aug 10.

13.

The effect of pentamidine on melanoma ex vivo.

Smith J, Stewart BJ, Glaysher S, Peregrin K, Knight LA, Weber DJ, Cree IA.

Anticancer Drugs. 2010 Feb;21(2):181-5. doi: 10.1097/CAD.0b013e3283340cee.

14.
15.

Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC).

Glaysher S, Yiannakis D, Gabriel FG, Johnson P, Polak ME, Knight LA, Goldthorpe Z, Peregrin K, Gyi M, Modi P, Rahamim J, Smith ME, Amer K, Addis B, Poole M, Narayanan A, Gulliford TJ, Andreotti PE, Cree IA.

BMC Cancer. 2009 Aug 27;9:300. doi: 10.1186/1471-2407-9-300.

16.

Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay.

Knight LA, Kurbacher CM, Glaysher S, Fernando A, Reichelt R, Dexel S, Reinhold U, Cree IA.

BMC Cancer. 2009 Jan 28;9:38. doi: 10.1186/1471-2407-9-38.

17.

Psychosocial treatments for attention-deficit/hyperactivity disorder.

Knight LA, Rooney M, Chronis-Tuscano A.

Curr Psychiatry Rep. 2008 Oct;10(5):412-8. Review.

PMID:
18803915
18.

Gonadoblastoma-associated mixed germ cell tumour in 46,XY complete gonadal dysgenesis (Swyer syndrome): analysis of Y chromosomal genotype and OCT3/4 and TSPY expression profile.

Ng SB, Yong MH, Knight LA, Lee VK, Nadarajah S, Stoop H, Looijenga LH.

Histopathology. 2008 Apr;52(5):644-6. doi: 10.1111/j.1365-2559.2008.02988.x. Epub 2008 Feb 23. No abstract available.

PMID:
18312345
19.

Comparison of long-term numerical and experimental total knee replacement wear during simulated gait loading.

Knight LA, Pal S, Coleman JC, Bronson F, Haider H, Levine DL, Taylor M, Rullkoetter PJ.

J Biomech. 2007;40(7):1550-8. Epub 2006 Nov 3.

PMID:
17084405
20.

Effect of culture conditions on the chemosensitivity of ovarian cancer cell lines.

Fernando A, Glaysher S, Conroy M, Pekalski M, Smith J, Knight LA, Di Nicolantonio F, Cree IA.

Anticancer Drugs. 2006 Sep;17(8):913-9.

PMID:
16940801
21.

The effect of imatinib mesylate (Glivec) on human tumor-derived cells.

Knight LA, Di Nicolantonio F, Whitehouse PA, Mercer SJ, Sharma S, Glaysher S, Hungerford JL, Hurren J, Lamont A, Cree IA.

Anticancer Drugs. 2006 Jul;17(6):649-55.

PMID:
16917210
22.

Biases in ratings of disruptive behavior in children: effects of sex and negative halos.

Hartung CM, Van Pelt JC, Armendariz ML, Knight LA.

J Atten Disord. 2006 May;9(4):620-30. Erratum in: J Atten Disord. 2007 Feb;10(3):332.

PMID:
16648229
23.

Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.

Knight LA, Conroy M, Fernando A, Polak M, Kurbacher CM, Cree IA.

Anticancer Drugs. 2005 Oct;16(9):969-76.

PMID:
16162973
24.

Cancer cell adaptation to chemotherapy.

Di Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, Fernando A, Glaysher S, Di Palma S, Johnson P, Somers SS, Toh S, Higgins B, Lamont A, Gulliford T, Hurren J, Yiangou C, Cree IA.

BMC Cancer. 2005 Jul 18;5:78.

25.

Rapid up-regulation of cyclooxygenase-2 by 5-fluorouracil in human solid tumors.

Mercer SJ, Di Nicolantonio F, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, Fernando A, Bhandari P, Somers SS, Toh SK, Cree IA; NHS Collaborative Research Programme on Predictive Oncology.

Anticancer Drugs. 2005 Jun;16(5):495-500.

PMID:
15846114
26.

The ex vivo characterization of XR5944 (MLN944) against a panel of human clinical tumor samples.

Di Nicolantonio F, Knight LA, Whitehouse PA, Mercer SJ, Sharma S, Charlton PA, Norris D, Cree IA.

Mol Cancer Ther. 2004 Dec;3(12):1631-7.

27.

The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.

Knight LA, Di Nicolantonio F, Whitehouse P, Mercer S, Sharma S, Glaysher S, Johnson P, Cree IA.

BMC Cancer. 2004 Nov 23;4:83.

28.

Ex vivo reversal of chemoresistance by tariquidar (XR9576).

Di Nicolantonio F, Knight LA, Glaysher S, Whitehouse PA, Mercer SJ, Sharma S, Mills L, Prin A, Johnson P, Charlton PA, Norris D, Cree IA.

Anticancer Drugs. 2004 Oct;15(9):861-9.

PMID:
15457126
29.

Ex vivo characterization of XR11576 (MLN576) against ovarian cancer and other solid tumors.

Di Nicolantonio F, Knight LA, Di Palma S, Sharma S, Whitehouse PA, Mercer SJ, Charlton PA, Norris D, Cree IA.

Anticancer Drugs. 2004 Oct;15(9):849-60.

PMID:
15457125
30.

Combination chemotherapy in advanced gastrointestinal cancers: ex vivo sensitivity to gemcitabine and mitomycin C.

Whitehouse PA, Mercer SJ, Knight LA, Di Nicolantonio F, O'Callaghan A, Cree IA; Portsmouth Upper GI and Colorectal Cancer Multidisciplinary Teams.

Br J Cancer. 2003 Dec 15;89(12):2299-304.

31.

Heterogeneity of chemosensitivity of esophageal and gastric carcinoma.

Mercer SJ, Somers SS, Knight LA, Whitehouse PA, Sharma S, Di Nicolantonio F, Glaysher S, Toh S, Cree IA; Portsmouth Upper GI Cancer Multi-Disciplinary Team.

Anticancer Drugs. 2003 Jul;14(6):397-403.

PMID:
12853879
32.

Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma.

Sharma S, Neale MH, Di Nicolantonio F, Knight LA, Whitehouse PA, Mercer SJ, Higgins BR, Lamont A, Osborne R, Hindley AC, Kurbacher CM, Cree IA.

BMC Cancer. 2003 Jul 3;3:19.

33.

Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumor chemosensitivity assay (ATP-TCA).

Whitehouse PA, Knight LA, Di Nicolantonio F, Mercer SJ, Sharma S, Cree IA; Portsmouth Colorectal Cancer Multidisciplinary Team.

Anticancer Drugs. 2003 Jun;14(5):369-75.

PMID:
12782944
34.

Use of an ATP-based chemosensitivity assay to design new combinations of high-concentration doxorubicin with other drugs for recurrent ovarian cancer.

Di Nicolantonio F, Neale MH, Knight LA, Lamont A, Skailes GE, Osborne RJ, Allerton R, Kurbacher CM, Cree IA.

Anticancer Drugs. 2002 Jul;13(6):625-30.

PMID:
12172508
35.

Humanitarian crises and old age: guidelines for best practice.

Knight LA.

Age Ageing. 2000 Jul;29(4):293-5. No abstract available.

PMID:
10985435
36.

Duplication of 8p with minimal phenotypic effect transmitted from a mother to her two daughters.

Gibbons B, Tan SY, Barber JC, Ng CF, Knight LA, Lam S, Ng I.

J Med Genet. 1999 May;36(5):419-22. No abstract available.

37.

Variants of chromosome 9 in phenotypically normal individuals.

Cheong KF, Knight LA, Tan M, Ng IS.

Ann Acad Med Singapore. 1997 May;26(3):312-4.

PMID:
9285024
38.

Partial monosomy for chromosome 22 in a girl with mental retardation.

Yong YP, Knight LA, Yong MH, Lam S, Ho LY.

Singapore Med J. 1997 Feb;38(2):85-6.

PMID:
9269370
39.

Subtle translocation (18;21) confirmed by FISH in a patient with Down syndrome.

Knight LA, Yong MH, Tan M, Ng IS.

Clin Genet. 1996 Nov;50(5):430-2.

PMID:
9007338
40.

Fanconi's anaemia and recurrent squamous cell carcinoma of the oral cavity: a case report.

Koo WH, Knight LA, Ang PT.

Ann Acad Med Singapore. 1996 Mar;25(2):289-92. Review.

PMID:
8799026
41.

Del(3) (p25.3) without phenotypic effect.

Knight LA, Yong MH, Tan M, Ng IS.

J Med Genet. 1995 Dec;32(12):994-5.

42.

Extra G positive band on the long arm of chromosome 9.

Knight LA, Soon GM, Tan M.

J Med Genet. 1993 Jul;30(7):613.

43.

Higher-order factors assessed by the ISI and PRF.

Lorr M, Knight LA.

J Clin Psychol. 1987 Jan;43(1):96-9.

PMID:
3558846
44.

Prenatal diagnosis of 45,X/46,XX mosaicism: true mosaicism in only one of four primary cultures.

Knight LA, Lawce H, Wcislo KL, Bannister VS.

Prenat Diagn. 1984 Mar-Apr;4(2):143-6.

PMID:
6739437
45.

Mosaic inversion duplication of chromosome 15 without phenotypic effect: occurrence in a father and daughter.

Knight LA, Lipson M, Mann J, Bachman R.

Am J Med Genet. 1984 Mar;17(3):649-54.

PMID:
6585144
46.

Maternal contamination in prenatal diagnosis.

Knight LA, Mann J.

Prenat Diagn. 1983 Apr-Jun;3(2):155-6. No abstract available.

PMID:
6622394
47.

Multiple karyotypic changes in retinoblastoma tumor cells: presence of normal chromosome No. 13 in most tumors.

Gardner HA, Gallie BL, Knight LA, Phillips RA.

Cancer Genet Cytogenet. 1982 Jul;6(3):201-11.

PMID:
7116318
48.

Familial retinoblastoma: segregation of chromosome 13 in four families.

Knight LA, Gardner HA, Gallie BL.

Am J Hum Genet. 1980 Mar;32(2):194-201.

49.

Absence of chromosome breakage in patients with retinoblastoma.

Knight LA, Gardner HA, Gallie BL.

Hum Genet. 1979 Sep 2;51(1):73-8.

PMID:
500095
50.

Segregation of chromosome 13 in retinoblastoma.

Knight LA, Gardner HA, Gallie BL.

Lancet. 1978 May 6;1(8071):989. No abstract available.

PMID:
76915

Supplemental Content

Loading ...
Support Center